{"name":"Rui-hua Xu, MD, PhD","slug":"rui-hua-xu-md-phd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBtMzNaWGVCeUxlTk5zWDBNZW5fS2tBVWV6MDluc3F5bVoxeVVEX1VjWEh1dWFaWmExWDZ3TG10UXJXN0paaUdaME0yTEhrUS1qZHVOQ0NHSVJ5Q0p4T3JF?oc=5","date":"2025-11-04","type":"trial","source":"Nature","summary":"Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research - Na","headline":"Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient g","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxOWm9oSzRkNVQxS3FlMlFjVTZ3VXBEOUR3SDE1QTEtYjdfSHF1SGFMVUZNNnZHWmtXcmFPaW5peEhDQ2hlYVYyYkxkQUNyT0dsLWFLZEZhdGszdnRIeEhPSmQxR1lHei1tU3RaQWVIaTJpTzFkUE9CZ1ZQTXQ1VTcwSG51U0cyc2dJb01rNURMQlh3SjFCOXJtYXpMbi16QTRhOTRaQjRubUczS3YtVEtjV2tHRG1LdXpxV1Y4U1N6eWVLb29rZmVHbWpKOXRpeDZI?oc=5","date":"2024-03-25","type":"trial","source":"The ASCO Post","summary":"Fruquintinib Plus Paclitaxel Under Study as Second-Line Treatment of Gastroesophageal Cancer - The ASCO Post","headline":"Fruquintinib Plus Paclitaxel Under Study as Second-Line Treatment of Gastroesophageal Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1kU2k1UWNlb1dkMzJFUzhtNEt4SmhtV01ra1RTYkNvcGRzd0RrT2dOcXBCZ0VWb1MzZ0Z4RUU1Sl9Zb2ZzV1ZlUV92djctNGp1TGt1LXJxNGpQM01EVmZwZUlpbXZsMG1tcWJkcWtVbjUzVUcybEE?oc=5","date":"2024-02-07","type":"pipeline","source":"MedPage Today","summary":"Mixed Results in Advanced Gastric/GEJ Cancer With Add-On Fruquintinib - MedPage Today","headline":"Mixed Results in Advanced Gastric/GEJ Cancer With Add-On Fruquintinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNS0VfaG5sbjUydEM3RWd5OE5qMXJWeThrZVU0TkV0VVJYNlUzX1duRlZSbEpIeFFnRVVIWE5DYTdyMjBBRjJEWnJCUXkydWRXWkdBUWNkNHlzbmFoek5WVDFhRlQ4OUhZcGQ0SnJURHBod0kxRHYxT09vNkc4X3VnY1htTnpfUFhfTk1oVDlZS3lxblM2UFJkUDl6VG8tOVpMbHlNeXRqX3AxMzRfWFZ5YzVhY2c5YS1jcTRndEhxeWtOQnphNmREUTdRYURYbkl2?oc=5","date":"2024-02-06","type":"pipeline","source":"OncLive","summary":"Second-Line Fruquintinib Plus Paclitaxel Significantly Improves PFS But Not OS in Advanced Gastric or GEJ Adenocarcinoma - OncLive","headline":"Second-Line Fruquintinib Plus Paclitaxel Significantly Improves PFS But Not OS in Advanced Gastric or GEJ Adenocarcinoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNTFl0bG5neTRvYWJJNE5UTWxVWnVMNkdRS20wRkstWHp2WWRoQWhuMFlkb1JCOUxBUHB0QVpIMnJHYmE3X1dLdUNDcndGU0JMQ0p3ME1MckN3WTRmTW56VkJSQTdCNjJOTjJkd3JEcUFMbGNUZjgxRUs0NnJXckVsR0owWVo4cHJYU0JsY3pYa2JwRnNiOTZXNWlBcw?oc=5","date":"2023-11-07","type":"pipeline","source":"OncLive","summary":"CMG901 Elicits Responses in CLDN18.2-Expressing Gastric/GEJ Cancer - OncLive","headline":"CMG901 Elicits Responses in CLDN18.2-Expressing Gastric/GEJ Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQcEI2bVNreUFBLTNxVDk1V0JWa0tPLUM3MUcwV01rZ0w1TWY3R3JWbjlMSEtOWHUxS0RKWEd0NU9fUWRlcTBFaUlLdFpUczR3T1VadlA3MENDYlRrSnJPMGN6bVNfWEliYXpWdjlRZFlGVnQxR0x2ZEoxY0NrQmdxMnNuTGFuWHR3VWN0MmNlMGRYd2dCRk9MQTIzSGhGckNTNVlwbGlnZDRUZWhKQnpYbU1TX3o1V21lRlFrTEJDYlJWMHdFaXAzM29lRmlPSVh4Q2NJ?oc=5","date":"2023-04-25","type":"trial","source":"The ASCO Post","summary":"GLOW Trial: Zolbetuximab Plus Chemotherapy Sets New Treatment Standard in Gastric Cancer Subset - The ASCO Post","headline":"GLOW Trial: Zolbetuximab Plus Chemotherapy Sets New Treatment Standard in Gastric Cancer Subset","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}